BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference in New York on Tuesday, June 24, 2014 at 10:00 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.